SCIENTIFIC INDUSTRIES INC: Annual Update

I’ve reviewed the latest report for Scientific Industries Inc. (SI). Here is the plain-English breakdown of what is happening under the hood.

1. What do they actually do?

Scientific Industries operates in two main areas:

• Benchtop Lab Equipment: They make precision weighing and counting tools under the "Torbal" brand. This includes analytical balances and the "VIVID" automated pill counter for pharmacies.
• Bioprocessing Systems: This is their high-growth, high-tech division. They create "Biotek" and "Sense" products—smart sensors, bioreactor controllers, and software. These tools help researchers monitor pH, oxygen, and biomass in real-time during cell culture and fermentation.

2. A Major Strategic Shift

In August 2025, the company finished a major restructuring. They sold their legacy "Genie" product line—including the famous Vortex-Genie mixer—for $9.6 million in cash. This move marks a pivot away from older, slow-growth hardware. They now focus entirely on high-profit bioprocessing and pharmacy automation. By selling the Genie line, they cut costs and shifted resources toward scaling their sensor technology and VIVID pharmacy systems.

3. Financial Health: The Hard Truth

The company is currently losing money during this transition. They reported a $1.2 million loss for fiscal year 2025, which is an improvement over the $6.4 million loss in 2024. Total revenue for 2025 reached about $8.8 million. Because they spend $2.5 million annually on research and development to stay competitive, their operating costs currently exceed their sales. They are using the cash from the Genie sale to fund this transition.

4. Key Risks to Keep in Mind

• The "Cash Crunch" Risk: The company has limited cash. Because they are losing money, management warns they may need to raise more capital. This would likely mean issuing more shares, which reduces your ownership percentage, or taking on more debt.
• The "Big Fish" Problem: Scientific Industries is a tiny company competing against giants like Sartorius and Eppendorf. These competitors have massive research budgets and global reach, making it hard for SI to compete with its specialized sensors.
• Concentration Risk: Revenue is not spread out. One single customer provided 31% of total revenue in 2025. If this customer leaves or cuts orders, the company will struggle to fund its operations.
• Thinly Traded Stock: The stock is rarely traded, sometimes seeing zero volume in a day. This makes the price jumpy and difficult to sell. You might find it hard to exit a large position without driving the share price down.

5. The Bottom Line

Scientific Industries is in a "make or break" phase. They have trimmed their business to focus on high-tech bioprocessing, but they are burning through cash to reach profitability. They are a small player in a market of giants. Their future depends on whether their new sensors become standard in pharmaceutical manufacturing.

If you are considering this, remember: you are betting on a turnaround that is still in its early stages. It comes with significant cash risks and a heavy reliance on a very small customer base. Before moving forward, weigh whether you are comfortable with the volatility of a thinly traded stock and the company's current need for outside capital to sustain its R&D efforts.